Short-term chemoprophylaxis with ceftizoxime vs. five-day aminoglycoside with metronidazole in 'contaminated' lower gastrointestinal surgery.
In a prospective, open, randomized controlled trial, 173 patients requiring surgery for potentially "contaminated" lower gastrointestinal surgery were allocated to receive either two doses of ceftizoxime (2 gm) with one dose of metronidazole (1.5 gm) or gentamicin 3 mg/kg/day for five days with one dose of metronidazole (1.5 gm). Eighty-nine patients received ceftizoxime and 84 patients received gentamicin. The groups were comparable with respect to diagnosis, procedure, type of anastomosis, and wound closure. The incidence of withdrawal due to failure to respond to the study drug (11.5 percent) was equivalent in the two groups. There was no difference in the overall incidence of postsurgical infection between the ceftizoxime and metronidazole group (22.2 percent) and the gentamicin and metronidazole group (25.7 percent). The incidence of wound infection (ceftizoxime and metronidazole, 6.9 percent; gentamicin and metronidazole, 10 percent) and deep sepsis (ceftizoxime and metronidazole, 15.3 percent; gentamicin and metronidazole, 15.7 percent) was similar.
Winslet
M C
MC
Department of Surgery, General Hospital, Birmingham, United Kingdom.
Youngs
D
D
Burdon
D W
DW
Keighley
M R
MR
D000617:Aminoglycosides / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000517:prevention & control*; D015296:Ceftizoxime / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D015994:Incidence; D007410:Intestinal Diseases / Q000382:microbiology / Q000601:surgery*; D008795:Metronidazole / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000517:prevention & control*; D011292:Premedication; D011446:Prospective Studies; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000517:prevention & control
D000617:Aminoglycosides; D008795:Metronidazole; D015296:Ceftizoxime